Found: 54
Select item for more details and to access through your institution.
Dihydroartemisinin Increases the Sensitivity of Photodynamic Therapy Via NF-κB/HIF-1α/Pathway in Esophageal Cancer Cell in vitro and in vivo.
- Published in:
- Cellular Physiology & Biochemistry (Karger AG), 2018, v. 48, n. 5, p. 2035, doi. 10.1159/000492541
- By:
- Publication type:
- Article
ANXA2 Silencing Inhibits Proliferation, Invasion, and Migration in Gastric Cancer Cells.
- Published in:
- Journal of Oncology, 2019, p. 1, doi. 10.1155/2019/4035460
- By:
- Publication type:
- Article
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00886-2
- By:
- Publication type:
- Article
Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, n. 1, p. 1, doi. 10.1186/s13045-017-0521-0
- By:
- Publication type:
- Article
Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-28408-3
- By:
- Publication type:
- Article
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 2, p. 315, doi. 10.1007/s10637-017-0536-y
- By:
- Publication type:
- Article
The influence of photodynamic therapy on the Warburg effect in esophageal cancer cells.
- Published in:
- Lasers in Medical Science, 2020, v. 35, n. 8, p. 1741, doi. 10.1007/s10103-020-02966-8
- By:
- Publication type:
- Article
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
- Published in:
- 2016
- By:
- Publication type:
- journal article
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2024, v. 73, n. 11, p. 1, doi. 10.1007/s00262-024-03806-2
- By:
- Publication type:
- Article
The anti-tumor effect of Newcastle disease virus HN protein is influenced by differential subcellular targeting.
- Published in:
- Cancer Immunology, Immunotherapy, 2010, v. 59, n. 7, p. 989, doi. 10.1007/s00262-010-0821-5
- By:
- Publication type:
- Article
Homocysteine induces procoagulant activity of red blood cells via phosphatidylserine exposure and microparticles generation.
- Published in:
- Amino Acids, 2014, v. 46, n. 8, p. 1997, doi. 10.1007/s00726-014-1755-6
- By:
- Publication type:
- Article
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2023, v. 330, n. 21, p. 2064, doi. 10.1001/jama.2023.19918
- By:
- Publication type:
- Article
Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.
- Published in:
- BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02841-7
- By:
- Publication type:
- Article
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 2, p. 1, doi. 10.1159/000526638
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 5, p. 500, doi. 10.1159/000516470
- By:
- Publication type:
- Article
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 4, p. 296, doi. 10.1159/000513486
- By:
- Publication type:
- Article
Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 5, p. 1681, doi. 10.1002/cam4.3771
- By:
- Publication type:
- Article
Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203).
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.684867
- By:
- Publication type:
- Article
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1238667
- By:
- Publication type:
- Article
First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
- Published in:
- International Journal of Cancer, 2023, v. 152, n. 4, p. 749, doi. 10.1002/ijc.34296
- By:
- Publication type:
- Article
Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma.
- Published in:
- Cancer Biology & Medicine, 2022, v. 19, n. 3, p. 358, doi. 10.20892/j.issn.2095-3941.2021.0388
- By:
- Publication type:
- Article
The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma.
- Published in:
- Cancer Biology & Medicine, 2021, v. 18, n. 2, p. 562, doi. 10.20892/j.issn.2095-3941.2020.0187
- By:
- Publication type:
- Article
MiR-590-5p inhibits colorectal cancer angiogenesis and metastasis by regulating nuclear factor 90/vascular endothelial growth factor A axis.
- Published in:
- Cell Death & Disease, 2016, v. 7, n. 10, p. e2413, doi. 10.1038/cddis.2016.306
- By:
- Publication type:
- Article
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
- Published in:
- JAMA: Journal of the American Medical Association, 2021, v. 326, n. 10, p. 916, doi. 10.1001/jama.2021.12836
- By:
- Publication type:
- Article
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Phase I study of the recombinant humanized anti-HER2 monoclonal antibody–MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors.
- Published in:
- Gastric Cancer, 2021, v. 24, n. 4, p. 913, doi. 10.1007/s10120-021-01168-7
- By:
- Publication type:
- Article
A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.
- Published in:
- Gastric Cancer, 2018, v. 21, n. 5, p. 782, doi. 10.1007/s10120-018-0809-y
- By:
- Publication type:
- Article
Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
- Published in:
- Gastric Cancer, 2016, v. 19, n. 1, p. 234, doi. 10.1007/s10120-015-0457-4
- By:
- Publication type:
- Article
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial.
- Published in:
- Signal Transduction & Targeted Therapy, 2024, p. 1, doi. 10.1038/s41392-024-01948-4
- By:
- Publication type:
- Article
Role of GSDMB in Pyroptosis and Cancer.
- Published in:
- Cancer Management & Research, 2020, v. 12, p. 3033, doi. 10.2147/CMAR.S246948
- By:
- Publication type:
- Article
Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study.
- Published in:
- Journal of Hematology & Oncology, 2017, v. 10, p. 1, doi. 10.1186/s13045-016-0384-9
- By:
- Publication type:
- Article
Chamaejasmine Arrests Cell Cycle, Induces Apoptosis and Inhibits Nuclear NF-κB Translocation in the Human Breast Cancer Cell Line MDA-MB-231.
- Published in:
- Molecules, 2013, v. 18, n. 1, p. 845, doi. 10.3390/molecules18010845
- By:
- Publication type:
- Article
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
- Published in:
- Oncologist, 2022, v. 27, n. 5, p. 342, doi. 10.1093/oncolo/oyab066
- By:
- Publication type:
- Article
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double‐Blinded, Placebo‐Controlled, Randomized Phase III Trial (ALTER0703).
- Published in:
- Oncologist, 2021, v. 26, n. 10, p. e1693, doi. 10.1002/onco.13857
- By:
- Publication type:
- Article
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial.
- Published in:
- Oncologist, 2019, v. 24, n. 8, p. e702, doi. 10.1634/theoncologist.2018-0839
- By:
- Publication type:
- Article
Efficacy and Safety of the FOLFOX4 Regimen Versus Doxorubicin in Chinese Patients With Advanced Hepatocellular Carcinoma: A Subgroup Analysis of the EACH Study.
- Published in:
- Oncologist, 2014, v. 19, n. 11, p. 1168, doi. 10.1634/theoncologist.2014-0190
- By:
- Publication type:
- Article
Clinical Trial Results. S-1 as Monotherapy or in Combination With Leucovorin as Second-Line Treatment in Gemcitabine-Refractory Advanced Pancreatic Cancer: A Randomized, Open-Label, Multicenter, Phase II Study.
- Published in:
- Oncologist, 2014, v. 19, n. 11, p. 1132, doi. 10.1634/theoncologist.2014-0223
- By:
- Publication type:
- Article
The Multicenter, Phase II Prospective Study of Paclitaxel Plus Capecitabine as First-Line Chemotherapy in Advanced Gastric Carcinoma.
- Published in:
- 2014
- By:
- Publication type:
- Abstract
Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1072943
- By:
- Publication type:
- Article
Neoadjuvant dose‐modified docetaxel in squamous cell carcinoma of the head and neck: A phase 3 study.
- Published in:
- Oral Diseases, 2020, v. 26, n. 2, p. 285, doi. 10.1111/odi.13252
- By:
- Publication type:
- Article
Anticancer Effects of Dihydroartemisinin on Human Esophageal Cancer Cells In Vivo.
- Published in:
- Analytical Cellular Pathology: Cellular Oncology, 2018, p. 1, doi. 10.1155/2018/8759745
- By:
- Publication type:
- Article
Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 18, p. 3137, doi. 10.1002/cncr.35377
- By:
- Publication type:
- Article
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 5, p. 995, doi. 10.1002/cncr.34019
- By:
- Publication type:
- Article
A single‐arm, multicenter, open‐label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 21, p. 3975, doi. 10.1002/cncr.33803
- By:
- Publication type:
- Article
Safety Profile and Adverse Events of Special Interest for Fruquintinib in Chinese Patients with Previously Treated Metastatic Colorectal Cancer: Analysis of the Phase 3 FRESCO Trial.
- Published in:
- Advances in Therapy, 2020, v. 37, n. 11, p. 4585, doi. 10.1007/s12325-020-01477-w
- By:
- Publication type:
- Article
Pyroptosis, a new bridge to tumor immunity.
- Published in:
- Cancer Science, 2021, v. 112, n. 10, p. 3979, doi. 10.1111/cas.15059
- By:
- Publication type:
- Article
Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. 1, doi. 10.3389/fonc.2020.00664
- By:
- Publication type:
- Article